REFERENCES
- Fine P G, Digre K B. A controlled trial of regional sympatholysis in the treatment of photo-oculodynia syndrome. J Neuroophthalmol 1995; 15: 90–94
- Dressler D, Saberi F A, Barbosa E R. Botulinum toxin: Mechanisms of action. Arq Neuropsiquiatr. 2005; 63: 180–185
- Elston J S. The use of botulinum toxin A in the treatment of strabismus. Trans Ophthalmol Soc U K. 1985; 104: 208–210, (Pt 2)
- Lennerstrand G, Nordbo O A, Tian S, Tian S, Eriksson-Derouet B, Ali T. Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand 1998; 76: 27–7
- Chang L B, Tsai C P, Liao K K, et al. Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62: 1–5
- Jost W H, Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 2001; 248: 21–24, (Suppl 1)
- Price J, Farish S, Taylor H, O'Day J. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology 1997; 104: 865–868
- Price J, O'Day J. Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm. Aust N Z J Ophthalmol 1994; 22: 255–260
- Park Y C, Lim J K, Lee D K, Yi S D. Botulinum A toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 1993; 8: 334–340
- Simpson L L. Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs. Biochimie. 2000; 82: 943–953
- Rubenstein E J. Botulinum toxin for headache. Int Ophthalmol Clin 2005; 45: 93–97
- Argoff C E. The use of botulinum toxins for chronic pain and headaches. Curr Treat Options Neurol 2003; 5: 483–492
- Guyuron B, Tucker T, Davis J. Surgical treatment of migraine headaches. Plast Reconstr Surg. 2002; 109: 2183–2189
- Guyuron B, Kriegler J S, Davis J, et al. Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg. 2005; 115: 1–9
- Kramer H H, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol. 2003; 250: 188–193
- Aoki K R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43: S9–15, (Suppl 1)
- Borodic G E, Acquadro M A. The use of botulinum toxin for the treatment of chronic facial pain. J Pain 2002; 3: 21–27
- Acquadro M A, Borodic G E. Botulinum toxin efficacy for the treatment of pain. J Clin Anesth. 2005; 17: 328–330
- Klein A W. The therapeutic potential of botulinum toxin. Dermatol Surg. 2004; 30: 452–455
- Tarsy D, Sudarsky L, Charness M E. Limb dystonia following electrical injury. Mov Disord. 1994; 9: 230–232
- Argoff C E. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain. Nov–Dec, 2002; 18: S177–81, (6 Suppl)
- Liu H T, Tsai S K, Kao M C, Hu J S. Botulinum toxin a relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med. Jan–Feb, 2006; 7(1)89–91
- Mulleners W M, Aurora S K, Chronicle E P, Stewart R, Gopal S, Koehler P J. Self-reported photophobic symptoms in migraineurs and controls are reliable and predict diagnostic category accurately. Headache Jan, 2001; 41(1)31–9
- Goadsby P J, Lipton R B, Ferrari M D. Migraine—Current understanding and treatment. N Engl J Med Jan 24, 2002; 346(4)257–70
- Rosenblatt M A, Sakol P J. Ocular and periocular pain. Otolaryngol Clin North Am Dec, 1989; 22(6)1173–203